Previous 10 | Next 10 |
Esperion (ESPR) recently reported mixed Q2 earnings with a beat on EPS and miss on revenue. The earnings were not enough for the market and ESPR continues lower. The company revealed that NEXLETOL and NEXLIZET had a strong quarter with a 67% increase in net revenue and a 28% increase ...
Esperion's sales following its twin therapy approval have been slow to develop. Esperion's products are entering a crowded marketplace with significant price competition. Esperion's potential reward for success is vast. For further details see: Esperion: Hunting Big Game...
Image source: The Motley Fool. Esperion Therapeutics, inc (NASDAQ: ESPR) Q2 2021 Earnings Call Aug 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics, inc (ESPR) Q2 2021 Earnings Call Transcrip...
Esperion Therapeutics, Inc. (ESPR) Q2 2021 Earnings Conference Call August 03, 2021 08:00 AM ET Company Participants Ben Church - Investor Relations & Corporate Communications Sheldon Koenig - President & Chief Executive Officer Joanne Foody - Chief Medical Officer Rick Bartram - Chie...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Esperion Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
– U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew 67% Sequentially to $10.6 Million – – Growth Driven by Increase in Demand and Substantial Improvement in Net Price ...
ALNY,AME,AQUA,ARNC,ATI,ATKR,AVNS,BABA,BEN,BHC,BLD,BP,CLX,CMI,COP,CRSR,CWEN,CWH,DD,DEA,DISCA,DNB,ESPR,ETN,ETRN,EXPD,FI,FIS,HEES,HLNE,HSC,HSIC,HSKA,IAA,IGT,INCY,INGR,IPGP,IT,KKR,LCII,LDOS,LGIH,LLY,LPX,MAR,MIME,MTRN,NKLA,NNN,NVT,OMI,OPCH,PBI,PCRX,PEG,PSX,PSXP,RCM,RHP,RL,ROCK,SABR,SAGE,SEE,SUN,SW...
ANN ARBOR, Mich., July 27, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer of Esperion will participate in the upcoming BTIG Virtual Biotechnology Conference. Live audio webcasts of these events can be access...
ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021. Following the release, company management will host a webcast and...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The short-squeeze rally in meme stocks like GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) is poised to go down in financial history books in terms of shareholder gains. However, a short squeeze is onl...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...